What is the GLP-1 receptor?
The GLP-1 receptor is a G-protein-coupled receptor expressed on pancreatic beta cells, gastric tissue, and central nervous system regions involved in appetite regulation. The molecular target of semaglutide and the broader long-acting GLP-1 agonist compound class. Tirzepatide engages it as one of two receptor arms (alongside the GIP receptor).
What the research literature says
The GLP-1 receptor is a Class B G-protein-coupled receptor that binds glucagon-like peptide 1 — a 30-31 amino-acid incretin hormone secreted by intestinal L-cells in response to nutrient intake. The receptor signals through Gαs with downstream cAMP-PKA pathway engagement, producing glucose-dependent insulin secretion from pancreatic beta cells, glucagon suppression, slowed gastric emptying, and centrally-mediated effects on appetite and food intake.
Long-acting GLP-1 agonists are engineered with backbone modifications for protease resistance plus fatty-acid sidechains for albumin-binding-mediated half-life extension. Semaglutide’s clinical-pharmacology was characterised across the SUSTAIN program in type 2 diabetes (PMID 28110911) and the STEP program in obesity (PMID 33567185). The Marso cardiovascular-outcomes trial established the cardiovascular-safety profile (PMID 27633186). The Lincoff SELECT trial extended the framework into obesity without diabetes (PMID 37952131).
The Willard tirzepatide pharmacology work characterised tirzepatide’s GLP-1 receptor engagement as similar to the established GLP-1 agonist class while the parallel GIP receptor engagement is biased and conformationally distinct (PMID 32730231).
Why this matters in research context
The GLP-1 receptor matters in peptide-research contexts as the molecular target of the entire long-acting GLP-1 agonist class. Researchers using semaglutide or tirzepatide for any metabolic-pharmacology research should anchor protocol design to GLP-1 receptor engagement; for tirzepatide research specifically, the parallel GIP receptor engagement adds the dual-mechanism dimension that distinguishes it from single-receptor compounds.
Related compounds
- Semaglutide 10mg — single-receptor GLP-1 agonist
- Tirzepatide 10mg — dual GIP + GLP-1 receptor agonist
Related research questions
References
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375(19):1834-1844. [PMID 27633186]
- Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol 2017;5(4):251-260. [PMID 28110911]
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384(11):989-1002. [PMID 33567185]
- Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020;5(17):e140532. [PMID 32730231]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.